Jean Zhao, Ph.D.
Affiliations: | Biological Chemistry and Molecular Pharmacology | Harvard Medical School, Boston, MA, United States |
Area:
PI3K, malignant transformationWebsite:
http://researchers.dana-farber.org/directory/profile.asp?pict_id=6939355Google:
"Jean Zhao"Cross-listing: Chemistry Tree
Children
Sign in to add traineeLukas Baitsch | post-doc | Harvard Medical School | |
Shom Goel | post-doc | Harvard Medical School |
Collaborators
Sign in to add collaboratorNational Brain Tumor Society | collaborator | National Brain Tumor Society |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Guarducci C, Nardone A, Russo D, et al. (2024) Selective CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
Bergholz JS, Wang Q, Wang Q, et al. (2023) PI3Kβ controls immune evasion in PTEN-deficient breast tumours. Nature |
Ding L, Wang Q, Martincuks A, et al. (2023) STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer. Journal For Immunotherapy of Cancer. 11 |
Wang Q, Bergholz JS, Ding L, et al. (2022) STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nature Communications. 13: 3022 |
Goel S, Bergholz JS, Zhao JJ. (2022) Targeting CDK4 and CDK6 in cancer. Nature Reviews. Cancer |
Ni J, Kabraji S, Xie S, et al. (2022) p16-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases. Nature Communications. 13: 1473 |
Gaglia G, Kabraji S, Rammos D, et al. (2022) Temporal and spatial topography of cell proliferation in cancer. Nature Cell Biology. 24: 316-326 |
Watt AC, Cejas P, DeCristo MJ, et al. (2021) CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. Nature Cancer. 2: 34-48 |
Spangle JM, Von T, Pavlick DC, et al. (2020) PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-α inhibition. Proceedings of the National Academy of Sciences of the United States of America |
Fassl A, Brain C, Abu-Remaileh M, et al. (2020) Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition. Science Advances. 6: eabb2210 |